

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sesptal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 BELISTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUB
NEWS 6 Apr 22 Records from IP.com available in CAPUS, HCAPUS, and ZCAPUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in CAPUS, HCAPUS, and ZCAPUS
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFUL has been reloaded
NEWS 12 Jun 10 FOREG no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
NEWS 14 Jul 29 Enhanced answer sets no longer valid
NEWS 15 Jul 30 NEFFIRST to be reloaded from STN
NEWS 16 Aug 08 PHARMARKETLETT (PHARMARK) - new on STN
NEWS 17 Aug 08 CANCERLIT reload
NEWS 18 Aug 08 NRTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUINE)
NEWS 20 Aug 19 now available on STN
NEWS 21 Aug 19 IFIPAT, IFICDB, and IFIUB have been reloaded
NEWS 22 Aug 26 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 23 Sep 03 Sequence searching in REGISTRY enhanced
NEWS 24 Sep 16 JAP10 has been reloaded and enhanced
NEWS 25 Sep 16 Experimental properties added to the REGISTRY file
NEWS 26 Sep 16 Indexing added to some pre-1967 records in CA/CAPUS
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.04,
CURRENT MACINTOSH VERSION IS V6.0a (ENG) AND V6.0Ja (JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:14:25 ON 02 OCT 2002

=> file medline, cancerlit, biosis, confsci, embase, caplus, uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 12:14:51 ON 02 OCT 2002

FILE 'CANCERLIT' ENTERED AT 12:14:51 ON 02 OCT 2002

FILE 'BIOSIS' ENTERED AT 12:14:51 ON 02 OCT 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 12:14:51 ON 02 OCT 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 12:14:51 ON 02 OCT 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'CAPUS' ENTERED AT 12:14:51 ON 02 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFUL' ENTERED AT 12:14:51 ON 02 OCT 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s syndecan(a)4

L1 585 SYNDECAN(A) 4

=> s 11 and angiogene?

L2 29 11 AND ANGIOGENE?

=> s 11 and fibronectin?

L3 83 11 AND FIBRONECTIN?

=> s 13 and inhibit

L4 10 13 AND INHIBIT

=> s 13 and inhibit?

L5 35 13 AND INHIBIT?

=> d 12 1-29

L2 ANSWER 1 OF 29 MEDLINE

AN 200460455 IN-PROCESS

DN 22126577 Pubmed ID: 12128069

TI A recombinant NH(2)-terminal heparin-binding domain of the adhesive

glycoprotein, thrombospondin-1, promotes endothelial tube formation and

cell survival: a possible role for syndecan-4

proteoglycan.

AU Ferrari do Outeiro-Bernstein Mariana A; Nunes Sara Santana; Andrade Ana

Carolina Magalhães; Alves Tercia Rodrigues; Legrand Chantal; Morandi

Veronica

Departamento de Biologia Celular e Genética, Instituto de Biologia Roberto

Alcantara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rua Sao

Francisco Xavier, 524 PHC sala 205, Maracanã, Rio de Janeiro, RJ, Brazil.

MATRIX BIOLOGY. (2002 Jun) 21 (4) 311-24.

SO Journal code: 9432592. ISSN: 0945-053X.

CY Germany: Germany, Federal Republic of
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20020911
 Last Updated on STN: 20020911

 L2 ANSWER 2 OF 29 MEDLINE
 AN 2001495375 PubMed ID: 11544026
 DN 21428909
 TI Syndecan-4 and focal adhesion function.
 AU Woods A; Couchman J R
 CS Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA.. awood@cellbio.bhs.uab.edu
 NC DK 54605 (NIDDK)
 SO CURRENT OPINION IN CELL BIOLOGY. (2001 Oct) 13 (5) 578-83. Ref: 57
 CY Journal code: 8913428. ISSN: 0955-0674.
 DT United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS General Review; (REVIEW)
 FS (REVIEW LITERATURE)
 ED Entered STN: 20010910
 Last Updated on STN: 20011015
 Entered Medline: 20011011

 L2 ANSWER 3 OF 29 MEDLINE
 AN 2001140784 PubMed ID: 1160142
 DN 21102376
 TI Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.
 AU Echtenmeyer F; Streit M; Wilcox-Adelman S; Saoncello S; Denhez F; Detmar M; Goettinck P
 CS Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
 NC CA69184 (NCI)
 HD-37490 (NIDDK)
 SO JOURNAL OF CLINICAL INVESTIGATION. (2001 Jan) 107 (2) R9-R14.
 CY Journal code: 7802877. ISSN: 0021-9738.
 DT United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Abstracted Index Medicus Journals; Priority Journals
 FS 200103
 ED Entered STN: 20010404
 Last Updated on STN: 20010404
 Entered Medline: 20010308

 L2 ANSWER 4 OF 29 MEDLINE
 AN 1998444445 PubMed ID: 9771483
 DN 98444445
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams T; De Vos R; David G; Van Damme B; Desmet V
 CS Laboratory for Histochemistry, University of Leuven, Belgium.
 SO JOURNAL OF PATHOLOGY. (1998 Jul) 185 (3) 290-7.
 CY Journal code: 0204634. ISSN: 0022-3417.
 ENGLAND: United Kingdom
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals

EM 199810
 ED Entered STN: 19981029
 Last Updated on STN: 19981029
 Entered Medline: 19981019

 L2 ANSWER 5 OF 29 CANCERLIT
 AN 1998444445
 DN 98444445 PubMed ID: 9771483
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams T; De Vos R; David G; Van Damme B; Desmet V
 CS Laboratory for Histochemistry, University of Leuven, Belgium.
 SO JOURNAL OF PATHOLOGY. (1998 Jul) 185 (3) 290-7.
 CY Journal code: 0204634. ISSN: 0022-3417.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Priority Journals
 OS MEDLINE 1998444445
 EM 199810
 ED Entered STN: 19981118
 Last Updated on STN: 19981118

 L2 ANSWER 6 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002-470155 BIOSIS
 DN PREV200200470155
 TI A recombinant NH2-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: A possible role for syndecan-4 proteoglycan.
 AU do Outeiro-Bernstein, Mariana A. Ferrari; Nunes, Sara Santana; Andrade, Ana Carolina Megalhaes; Alves, Tercia Rodrigues; Legrand, Chantal; Morandi, Veronica (1)
 CS (1) Departamento de Biologia Celular e Genetica, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rua Sao Francisco Xavier, 524, Maracana, PHC Sala 205, Rio de Janeiro, RJ: veronica@uerj.br Brazil
 SO Matrix Biology. (June, 2002) Vol. 21, No. 4, pp. 311-324.
 http://www.elsevier.com/locate/matrix. print.
 ISSN: 0945-053X.
 DT Article
 LA English

 L2 ANSWER 7 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002-428611 BIOSIS
 DN PREV200200428611
 TI Modulation of microvascular signaling by heparan sulfate matrix: Studies in syndecan-4 transgenic mice.
 AU Li, Jian; Parovian, Chohren; Li, Jiaany; Hampton, Thomas G.; Metals, Caroline; Trachenko, Eugene; Seljke, Frank W.; Simons, Michael (1)
 CS (1) Angiogenesis Research Center and Section of Cardiology, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, Lebanon, NH, 03756; Michael.Simons@dartmouth.edu USA
 SO Microvascular Research. (July, 2002) Vol. 64, No. 1, pp. 38-46.
 http://www.academypress.com/micpath. print.
 ISSN: 0026-2862.
 DT Article
 LA English

 L2 ANSWER 8 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002-263200 BIOSIS
 DN PREV200200263200
 TI Syndecan-4 dependent manner: Cross-talk between PKC isozymes.

AU Murakami, Masahiro (1); Horowitz, Arle; Simons, Michael
 CS (1) Dartmouth-Hitchcock Med Ctr, Lebanon, NH USA
 SO Circulation, (October 23, 2001) Vol. 104, No. 17 Supplement, pp. II-34.
 http://circ.ahajournals.org/. print.
 Meeting Info.: Scientific Sessions 2001 of the American Heart Association
 Anaheim, California, USA November 11-14, 2001
 ISSN: 0009-7322.

DT Conference
 LA English

L2 ANSWER 9 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001.83295 BIOSIS
 DN PREV200100083295
 TI Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.
 AU Scheremeyer, Frank; Streif, Michael; Wilcox-Adelman, Sarah; Saoncelia, Stefania; Denhez, Fabienne; Delmar, Michael; Goetlinck, Paul F. (1)
 CS (1) Cutaneous Biology Research Center, MGH-East, 13th Street, Building 149, Charlestown, MA, 02129; paul.goetlinck@chrc2.mgh.harvard.edu USA
 SO Journal of Clinical Investigation, (January, 2001) Vol. 107, No. 2, pp. R9-R14. print.
 ISSN: 0021-9738.

DT Article
 LA English
 SL English

L2 ANSWER 10 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2000.304026 BIOSIS
 DN PREV200000304026
 TI Syndecan signaling in angiogenesis.
 AU Simons, Michael (1)
 CS (1) Angiogenesis Research Center, BIDMC, Harvard Medical School, Boston, MA USA
 SO FASEB Journal, (March 15, 2000) Vol. 14, No. 4, pp. A799. print.
 Meeting Info.: Annual Meeting of Professional Research Scientists: Experimental Biology 2000 San Diego, California, USA April 15-18, 2000
 Federation of American Societies for Experimental Biology
 . ISSN: 0892-6638.

DT Conference
 LA English
 SL English

L2 ANSWER 11 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1999.524045 BIOSIS
 DN PREV199900524045
 TI Syndecan-4 cytoplasmic domain-dependent regulation of endothelial cell growth.
 AU Volk, Ruediger (1); Li, Jian (1); Schwartz, Jay; Horowitz, Arle; Simons, Michael (1)
 CS (1) BIDMC/Harvard Med. Sch., Boston, MA USA
 SO Circulation, (Oct. 27, 1998) Vol. 98, No. 17 SUPPL., pp. 1391.
 Meeting Info.: 71st Scientific Sessions of the American Heart Association Dallas, Texas, USA November 8-11, 1998 The American Heart Association
 . ISSN: 0009-7322.

DT Conference
 LA English

L2 ANSWER 12 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998.394318 BIOSIS
 DN PREV199800394318
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams, Tania (1); De Vos, Rita; Van Damme, Guido David Boudewijn; Desmet, Valere
 CS (1) Lab. Histo- Cytochem., Univ. Leuven, Mindebroederstr. 23, B-3000

SO Leuven Belgium
 CS Journal of Pathology, (July, 1998) Vol. 185, No. 3, pp. 290-297.
 ISSN: 0022-3417.

DT Article
 LA English

L2 ANSWER 13 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001311467 EMBASE
 TI Syndecan-4 and focal adhesion function.
 AU Woods A.; Cochman J.R.
 CS A. Woods, Department of Cell Biology, University of Alabama, Birmingham, AL 35294-0019, United States. awoods@cellbio.bhs.uab.edu
 SO Current Opinion in Cell Biology, (1 Oct 2001) 13/5 (578-583).
 Refs: 57
 ISSN: 0955-0674 CODEN: COCBE3

DT United Kingdom
 LA English
 SL English

L2 ANSWER 14 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001037199 EMBASE
 TI Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.
 AU Scheremeyer F.; Streif M.; Wilcox-Adelman S.; Saoncelia S.; Denhez F.; Delmar M.; Goetlinck P.F.
 CS P.F. Goetlinck, Cutaneous Biology Research Center, MGH-East, Building 149, 13th Street, Charlestown, MA 02129, United States.
 paul.goetlinck@chrc2.mgh.harvard.edu
 SO Journal of Clinical Investigation, (2001) 107/2 (R9-R14).
 Refs: 25
 ISSN: 0021-9738 CODEN: JCINAO

DT United States
 LA English
 SL English

L2 ANSWER 15 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998233281 EMBASE
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams T.; De Vos R.; David G.; Van Damme B.; Desmet V.
 CS Dr. T. Roskams, Lab. for Histo- and Cytochemistry, University of Leuven, Mindebroederstraat 12, B-3000 Leuven, Belgium
 SO Journal of Pathology, (1998) 185/3 (290-297).
 Refs: 35
 ISSN: 0022-3417 CODEN: JPTLAS

DT United Kingdom
 LA English
 SL English

L2 ANSWER 16 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 9736357 EMBASE
 DN 1997336357
 TI Macrophage-dependent regulation of syndecan gene expression.
 AU Li J.; Brown L.F.; Laham R.J.; Volk R.; Simons M.
 CS Dr. M. Simons, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, United States.

| | |
|--|---|
| SO | Birmingham, AL, 35294-0019, USA |
| BI | Current Opinion in Cell Biology (2001), 13(5), 578-583 |
| CO | CODEN: COCBEJ; ISSN: 0955-0674 |
| PB | Elsevier Science Ltd. |
| PT | JT Journal; General Review |
| LA | English |
| RE CNT | 57 |
| THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD | |
| ALL CITATIONS AVAILABLE IN THE RE FORMAT | |
| L2 | ANSWER 20 OF 29 CAPLUS COPYRIGHT 2002 ACS |
| AN | 2001:416975 |
| DN | 135:37179 |
| TI | Proteoglycans and pharmaceutical compositions comprising them |
| IN | Yaron, Avner |
| PA | Teda Research and Development Co. Ltd., Israel |
| SO | PCT Int. Appl., 40 pp. |
| CODEN: | PIXXD2 |
| DT | Patent |
| LA | English |
| FAN CNT | 1 |
| PATENT NO. | KIND DATE APPLICATION NO. DATE |
| PI | WO 2001040267 A2 20010607 WO 2000-11821 20001205 |
| MO | 2001040267 A3 20020071 |
| M: | AE, AC, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, |
| | CR, CC, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GO, GE, GM, HR, |
| | HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, |
| | LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, |
| | SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, |
| | YU, ZA, ZW, AM, AZ, AY, KG, KZ, MD, RT, TU, TW |
| RN: | GH, GM, KE, LS, MM, MZ, SD, SL, SZ, T2, TG, ZW, AT, BE, CH, CY, |
| DE, DK, ES, FI, FR, GA, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, | |
| BJ, CF, CG, CI, CM, GAB, GN, GW, ML, MR, NE, SN, TD, TG | |
| EP 1237922 A2 20020911 EP 2000-979926 20001205 | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | |
| IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | |
| PRAI II, 1999-133316 A 19991205 | |
| MO 2000-11821 W 20001205 | |
| L2 | ANSWER 21 OF 29 CAPLUS COPYRIGHT 2002 ACS |
| AN | 2001:48429 |
| DN | 134:176534 |
| TI | Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4 |
| AU | Echtemeyer, Frank; Streif, Michael; Wilcox-Adelman, Sarah; Saoncelia, |
| CS | Stehman, Denzer; Fabienne; Dermar, Michæl; Goerlinck, Paul F. |
| SO | Medical School, Charlestown, MA, USA |
| SO | Journal of Clinical Investigation (2001), 107(2), R9-R14 |
| CODEN: | JCINAO; ISSN: 0021-9738 |
| PB | American Society for Clinical Investigation |
| DT | Journal |
| LA | English |
| RE CNT | 25 |
| THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD | |
| ALL CITATIONS AVAILABLE IN THE RE FORMAT | |
| L2 | ANSWER 22 OF 29 CAPLUS COPYRIGHT 2002 ACS |
| AN | 2000:1335257 |
| DN | 133:823 |
| TI | Stimulation of angiotensin via syndecan-4 |
| IN | Cytoplasmic domain signaling pathway |
| NM | Slimons, Michael; Horowitz, Arie |
| PA | Beth Israel Deaconess Medical Center, USA |
| PCT Int. Appl., | 73 pp. |
| SO | |

CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 2000027416 | A1 | 20000518 | WO 1999-US26647 | 19991110 |
| W: AU, CA, JP | | | | |
| RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP 1131081 | A1 | 20010912 | EP 1999-962741 | 19991110 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE, FI | | | | |
| PRAI US 1998-190976 | A | 19981112 | | |
| WO 1999-US26647 | W | 19991110 | | |
| RE.CNT 6 | | | | |
| THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD | | | | |
| ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

L2 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:175824 CAPLUS
 DN 132:217982
 TI Stimulation of angiogenesis via enhanced endothelial expression of chimeric heparan sulfate-binding proteins
 IN Simons, Michael; Volk, Rudiger; Horowitz, Arle
 PA Beth Israel Deaconess Medical Center, USA
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 2000014103 | A1 | 20000316 | WO 1999-US18665 | 19990818 |
| W: AU, CA, JP | | | | |
| RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9956794 | A1 | 20000327 | AU 1999-56794 | 19990818 |
| EP 1112283 | A1 | 20010704 | EP 1999-943760 | 19990818 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE, FI | | | | |
| PRAI US 1998-145916 | A | 19980902 | | |
| WO 1999-US18665 | W | 19990818 | | |
| RE.CNT 3 | | | | |
| THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD | | | | |
| ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

L2 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:357168 CAPLUS
 DN 125:26311
 TI Syndecan (syndecan expression-inducers) mediate modulation of tissue repair
 IN Gallo, Richard L.; Bernfield, Merton
 PA Children's Medical Center Corporation, USA
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 9609322 | A2 | 19960328 | WO 1995-US12080 | 19950922 |
| WO 9609322 | A3 | 19960328 | | |
| W: AU, CA, JP, KR | | | | |
| RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 5654273 | A | 19970805 | US 1994-310722 | 19940922 |

AU 9538228 A1 19960409 AU 1995-38228 19950922
 US 5863897 19990126
 PRAI US 1994-310722 A 19940922
 WO 1995-US12080 19950922

L2 ANSWER 25 OF 29 USPATFULL
 AN 2002:112871 USPATFULL
 TI Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
 IN Franco, Wayne P.; Rocky Hill, CT, UNITED STATES
 PI US 2002058612 A1 20020516
 AI US 2001-828330 A1 20010406 (9)
 PRAI US 2000-195624P 20000406 (60)
 DT Utility
 FS APPLICATION

LN.CNT 2636
 INCL INCLM: 514/002.000
 INCLS: 424/043.000
 NCLM: 514/002.000
 NCL NCLM: 424/043.000
 IC [7]
 ICM: A61K009-04
 ICS: A61K038-18

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 29 USPATFULL
 AN 2002:92068 USPATFULL
 TI Methods of modulating wound healing and angiogenesis
 IN Goetlinck, Paul F.; Boston, MA, UNITED STATES
 PI US 2002048585 A1 20020425
 AI US 2001-900288 A1 20010706 (9)
 PRAI US 2000-216247P 20000706 (60)
 DT Utility
 FS APPLICATION

LN.CNT 1486
 INCL INCLM: 424/155.100
 INCLS: 514/012.000; 514/044.000
 NCLM: 424/155.100
 NCL NCLM: 514/012.000; 514/044.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K039-395; A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 29 USPATFULL
 AN 2002:22428 USPATFULL
 TI Neoglycan anticancer agents and uses thereof
 IN Sanderson, Ralph D.; Maumelle, AR, UNITED STATES
 PI US 2002013264 A1 20020131
 AI US 2001-921032 A1 20010802 (9)
 PRAI Continuation-in-part of Ser. No. US 2000-479139, filed on 7 Jan 2000, PENDING
 DT Utility
 FS APPLICATION

LN.CNT 1334
 INCL INCLM: 514/002.000
 INCLS: 514/054.000; 514/056.000; 514/059.000
 NCLM: 514/002.000
 NCL NCLM: 514/054.000; 514/056.000; 514/059.000
 IC [7]
 ICM: A61K038-00

ICS: A61K031-728; A61K031-727; A61K031-726; A61K031-721; A61K031-737
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 28 OF 29 USPATFULL
AN 1999:12906 USPATFULL
TI Synchronic mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
PA Benfield, Metron, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. Corporation)
PI US 5863897 19990126
AI US 1996-728333 19961010 (8)
RLI Continuation of Ser. No. US 1994-310722, filed on 22 Sep 1994, now patented. Pat. No. US 5654273

DT Utility
FS Granted
LN.CNT 666
INCL INCLM: 514/012.000
INCLM: 514/008.000
NCLM: 514/012.000
NCLM: 514/008.000
IC [6]

ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K007-00
EXF 514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 29 OF 29 USPATFULL
AN 97:68443 USPATFULL
TI Synchronic mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
PA Benfield, Metron, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. Corporation)
PI US 5654273 19970805
AI US 1994-310722 19940922 (8)
DT Utility
FS Granted
LN.CNT 748

INCL INCLM: 514/012.000
INCLM: 514/008.000; 530/324.000
NCLM: 514/012.000
NCLM: 514/008.000; 530/324.000
IC [6]

ICM: A61K038-00
ICS: C07K005-00; C07K007-00; C07K017-00
EXF 514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:14:25 ON 02 OCT 2002)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULL'
ENTERED AT 12:14:51 ON 02 OCT 2002
L1 585 S SYNDICAN(A)4
L2 29 S L1 AND ANGIOGENE?
L3 83 S L1 AND FIBRONECTIN?
L4 10 S L3 AND INHIBIT
L5 35 S L3 AND INHIBIT?
=> d 14 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 2000:666752 CAPLUS
DN 133:232876

TI Methods of modulating cell attachment and migration using a modulator of
IN Syndecan-4 ectodomain binding with a counterligand
IN Goetnick, Paul
PA The General Hospital Corporation, USA
SO PCT Int. Appl., 61 pp.
DT Patent
LA English
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2000055181 A1 20000921 WO 2000-056740 20000315
W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE
PRAI US 1999-124396P P 19990315
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 USPATFULL

AN 2002:221323 USPATFULL
TI Molecular toxicology modeling
IN Mendrick, Donna L., Mount Airy, MD, UNITED STATES
IN Porter, Mark W., Germantown, MD, UNITED STATES
IN Johnson, Kory R., Bethesda, MD, UNITED STATES
IN Castle, Arthur L., Washington, DC, UNITED STATES
IN Elashoff, Michael R., Germantown, MD, UNITED STATES
PI US 2002119462 A1 20020829
AI US 2001-917800 A1 20010731 (9)
PRAI US 2000-222040P 20000731 (60)
US 2000-244880P 20001102 (60)
US 2001-280029P 20010511 (60)
US 2001-280645P 20010515 (60)
US 2001-292336P 20010522 (60)
US 2001-295798P 20010606 (60)
US 2001-297457P 20010613 (60)
US 2001-298884P 20010619 (60)
US 2001-303459P 20010709 (60)

DT Utility
FS APPLICATION
LN.CNT 9801
INCL INCLM: 435/006.000
INCLM: 702/020.000
NCLM: 435/006.000
NCLM: 702/020.000
IC [7]

ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL
AN 2002:206116 USPATFULL
TI Toxicant-induced differential gene expression
IN Reidhaat-Olson, John F., Montclair, NJ, UNITED STATES
PI US 2002110808 A1 20020815
AI US 2000-489220 A1 20000121 (9)
DT Utility
FS APPLICATION
LN.CNT 5161
INCL INCLM: 435/006.000
INCLM: 435/091.200; 536/023.100

NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/023.100

IC [7]
ICM: C120001-68
ICS: C07H021-02; C07H021-04; C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPTAFULL
AN 2002:92068 USPTAFULL
TI Methods of modulating wound healing and angiogenesis
IN Goelink, Paul F., Boston, MA, UNITED STATES
PI US 2002048585 A1 20020425
AI US 2001-900288 A1 20010706 (9)
PRAI US 2000-216247P 20000706 (60)
DT Utility
FS APPLICATION
LN.CNT 1486
INCL INCLM: 424/155.100
INCLS: 514/012.000; 514/044.000
NCL NCLM: 424/155.100
NCLS: 514/012.000; 514/044.000

IC [7]
ICM: A61K048-00
ICS: A61K039-395; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPTAFULL
AN 2002:22107 USPTAFULL
TI POLYPEPTIDES WITH A4 INTEGRIN SUBUNIT RELATED ACTIVITY
IN MCCARTHY, JAMES B., MINNEAPOLIS, MN, UNITED STATES
FURCHT, LEO T., MINNEAPOLIS, MN, UNITED STATES
IIDA, JOJI, SHOREVIEW, MN, UNITED STATES
PA Regents of the University of Minnesota, Minneapolis, MN (U.S. corporation)
PI US 2002012942 A1 20020131
AI US 1998-10714 A1 19980122 (9)
DT Utility
FS APPLICATION
LN.CNT 1102
INCL INCLM: 435/007.100
INCLS: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
427/002.100; 623/001.100
NCL NCLM: 435/007.100
NCLS: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
427/002.100; 623/001.100

IC [7]
ICM: A61K038-00
ICS: A61K038-04; C07K017-00; C07K016-00; C07K014-00; C07K005-00;
C07K004-00; C07K002-00; C07K007-00; C12M001-00; C01N033-53; A61L002-00;
A61F002-06; B05D003-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPTAFULL
AN 2000:18280 USPTAFULL
TI Nucleic acid sequence of senescence associated gene
IN Funk, Walter, Hayward, CA, United States
PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
PI US 6025194 20000215
AI US 1997-974180 19971119 (8)
DT Utility
FS Granted
LN.CNT 4667
INCL INCLM: 435/320.100
INCLS: 536/023.100; 536/023.500; 536/024.100; 435/320.100; 435/325.000

NCL NCLM: 435/320.100
NCLS: 435/325.000; 536/023.100; 536/023.500; 536/024.100

IC [7]
ICM: C07H021-04
ICS: C12N015-63; C12N015-85; C12N015-11
536/23.5; 536/23.1; 536/24.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPTAFULL
AN 1999:12906 USPTAFULL
TI Synectin mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
Bernfield, Merton, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5863897 19990126
AI US 1996-728333 19961010 (8)
RLI Continuation of Ser. No. US 1994-310722, filed on 22 Sep 1994, now patented, Pat. No. US 5654273
DT Utility
FS Granted
LN.CNT 666
INCL INCLM: 514/012.000
INCLS: 514/008.000
NCL NCLM: 514/012.000
NCLS: 514/008.000

IC [6]
ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K007-00
514/12; 514/8; 530/324
EXF 514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPTAFULL
AN 1998:15925 USPTAFULL
TI Suppression of tumor cell growth by syndecan-1 ectodomain
IN Jalkanen, Markku, Espoo, Finland
Mali, Markku, Salo, Finland
PA Biote Therapies Ltd., Turku, Finland (non-U.S. corporation)
PI US 5851993 19981222
AI US 1995-488199 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-258862, filed on 13 Jun 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1585
INCL INCLM: 514/012.000
INCLS: 514/008.000; 514/021.000; 530/395.000
NCL NCLM: 514/012.000
NCLS: 514/008.000; 514/021.000; 530/395.000

IC [6]
ICM: A61K038-17
ICS: A61K038-16; C07K014-47; C07K014-705
514/8; 514/12; 514/21; 436/64; 530/380; 530/395; 530/808; 530/827
EXF 514/8; 514/12; 514/21; 436/64; 530/380; 530/395; 530/808; 530/827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 10 USPTAFULL
AN 97:68443 USPTAFULL
TI Synectin mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
Bernfield, Merton, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5654273 19970805
AI US 1994-310722 19940922 (8)

DT Utility
FS Granted
LN.CNT 748
INCL INCLM: 514/012.000
NCL INCLM: 514/008.000; 530/324.000
NCLM: 514/012.000
NCLS: 514/008.000; 530/324.000
IC [6]
ICM: A61K038-00
ICS: C07K005-00; C07K007-00; C07K017-00
EXF 514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULTL
967785 USPATFULTL
TI Construction and use of synthetic constructs encoding syndecan
IN Saunders, Scott, Boston, MA, United States
Bernfield, Merton, Boston, MA, United States
Kato, Masato, Boston, MA, United States
PA The Board of Trustees of the Ireland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5486599 19960123
AI US 1993-78683 19930617 (8)
RLI Continuation-in-part of Ser. No. US 1991-757654, filed on 6 Sep 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-856869, filed on 24 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-746797, filed on 12 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-311585, filed on 29 Mar 1989, now abandoned
DT Utility
FS Granted
LN.CNT 3939
INCL INCLM: 530/395.000
NCL INCLM: 530/023.500; 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400; 536/023.500; 935/010.000; 935/047.000; 935/050.000; 935/070.000
NCLM: 530/395.000
NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400; 536/023.500
IC [6]
ICM: C07K014-435
ICS: C07K019-00; C12N015-12; C12N015-62
EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
(FILE 'HOME' ENTERED AT 12:14:25 ON 02 OCT 2002)
FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULTL'
ENTERED AT 12:14:51 ON 02 OCT 2002
L1 585 S SYNDSCAN(A)4
L2 29 S L1 AND ANGIOGENE?
L3 83 S L1 AND FIBROGENE?
L4 10 S L3 AND INHIBIT
L5 35 S L3 AND INHIBIT?
=> d 15 1-35
L5 ANSWER 1 OF 35 MEDLINE
AN 2002460455 IN-PROCESS
DN 22126577 Pubmed ID: 12128069

TI A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4
AU Ferrari do Outeiro-Bernstein Mariana A; Nunes Sara Santana; Andrade Ana Carolina Magalhães; Alves Tercia Rodrigues; Legrand Chantal; Morandi Veronica
CS Departamento de Biologia Celular e Genética, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rua São Francisco Xavier, 524 PHLG sala 205, Maracana, Rio de Janeiro, RJ, Brazil.
SO MATRIX BIOLOGY, (2002 Jun) 21 (4) 311-24.
JOURNAL code: 9432592. ISSN: 0945-053X.
CY Germany; Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20020911
Last Updated on STN: 20020911

L5 ANSWER 2 OF 35 MEDLINE
AN 2002448107 IN-PROCESS
DN 22194361 Pubmed ID: 12087088
TI Syndecan-4 modulates focal adhesion kinase phosphorylation.
AU Wilcox-Adelman Sarah A; Denhez Fabienne; Goettlck Paul F
CS Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2002 Sep 6) 277 (36) 32970-7.
JOURNAL code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20020904
Last Updated on STN: 20020904

L5 ANSWER 3 OF 35 MEDLINE
AN 2001689481 MEDLINE
DN 21587766 Pubmed ID: 11731446
TI Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.
AU Huang W; Chiquet-Ehrismann R; Moyano J V; Garcia-Pardo A; Orend G
CS Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland.
SO CANCER RESEARCH, (2001 Dec 1) 61 (23) 8586-94.
JOURNAL code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 20011212
Last Updated on STN: 20020125
Entered Medline: 20020103

L5 ANSWER 4 OF 35 MEDLINE
AN 2001551530 MEDLINE
DN 21482060 Pubmed ID: 11598898
TI PR-39 coordinates changes in vascular smooth muscle cell adhesive strength and locomotion by modulating cell surface heparan sulfate-matrix interactions.
AU Chon J H; Houston M M; Xu C; Chaikof E L
CS School of Chemical Engineering, Georgia Institute of Technology, Atlanta.

Georgia, USA.
HL60963 (NHLBI)
NC JOURNAL OF CELLULAR PHYSIOLOGY, (2001 Nov) 189 (2) 133-43.
SO Journal code: 0050222. ISSN: 0021-9541.
CY United States
DT Journal, Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 20011015
Last Updated on STN: 20011029
Entered Medline: 20011025

ANSWER 5 OF 35 MEDLINE
L5 1999178970
AN 99178970 PubMed ID: 10077592
DN syndecan-4 signals cooperatively with integrins in a
TI Rho-dependent manner in the assembly of focal adhesions and actin stress
fibers.
AU Saponcella S; Echtermeyer F; Demhez F; Nowlen J K; Mosher D F; Robinson S
CS D; Hynes R O; Goetlinck P F
Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard
Medical School, Charlestown, MA 02129, USA.
NC HD-22016 (NICHHD)
HL21644 (NHLBI)

PO-H41484 (NHLBI)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA. (1999 Mar 16) 96 (6) 2805-10.
CY Journal code: 7505876. ISSN: 0027-8424.
DT United States
DT Journal, Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199905
ED Entered STN: 19990601
Last Updated on STN: 20000303
Entered Medline: 19990520

ANSWER 6 OF 35 CANCERLIT
L5 2002097321
AN 21587766 PubMed ID: 11731446
DN Interference of tenascin-C with *syndecan-4* binding to
TI fibronectin blocks cell adhesion and stimulates tumor cell
proliferation.
AU Huang W; Chiquet-Ehrismann R; Moyano J V; Garcia-Pardo A; Orend G
CS Friedrich Miescher Institute for Biomedical Research, 4058 Basel,
Switzerland.
SO CANCER RESEARCH. (2001 Dec 1) 61 (23) 8586-94.
CY Journal code: 2984705R. ISSN: 0008-5472.
DT United States
DT Journal, Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE: Priority Journals
OS MEDLINE 2001689481
EM 200201
ED Entered STN: 20020726
Last Updated on STN: 20020726

ANSWER 7 OF 35 CANCERLIT
L5 2002081050
AN 21482060 PubMed ID: 11598898
DN PR-39 coordinates changes in vascular smooth muscle cell adhesive strength
TI and locomotion by modulating cell surface heparan sulfate-matrix
interactions.

Chon J H; Houston M M; Xu C; Chaikof E L
CS School of Chemical Engineering, Georgia Institute of Technology, Atlanta,
Georgia, USA.
NC HL60963 (NHLBI)
SO JOURNAL OF CELLULAR PHYSIOLOGY, (2001 Nov) 189 (2) 133-43.
CY Journal code: 0050222. ISSN: 0021-9541.
DT United States
DT Journal, Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE: Priority Journals
OS MEDLINE 2001551530
EM 200110
ED Entered STN: 20020726
Last Updated on STN: 20020726

ANSWER 8 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
L5 2002:470155 BIOSIS
AN PREV200200470155
DN A recombinant NH2-terminal heparin-binding domain of the adhesive
TI glycoprotein, thrombospondin-1, promotes endothelial tube formation and
cell survival: A possible role for *syndecan-4*
proteoglycan.
AU do Oureiro-Bernstein, Mariana A. Ferrari; Nunes, Sara Santana; Andrade,
Ana Carolina Magalhães; Alves, Tercia Rodrigues; Degrand, Chantal;
Morandi, Veronica (1)
CS (1) Departamento de Biologia Celular e Genética, Instituto de Biologia
Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro (UERJ),
Rua São Francisco Xavier, 524, Maracanã, PHC Sala 205, Rio de Janeiro,
RJ: veronica@uerj.br Brazil
SO Matrix Biology. (June, 2002) Vol. 21, No. 4, pp. 311-324.
http://www.elsevier.com/locate/matrix. print.
ISSN: 0945-053X.

DT English
LA English

ANSWER 9 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
L5 2002:38297 BIOSIS
AN PREV20020038297
DN Interference of tenascin-C with *syndecan-4* binding to
TI fibronectin blocks cell adhesion and stimulates tumor cell
proliferation.
AU Huang, Wentao; Chiquet-Ehrismann, Ruth; Moyano, Jose V.; Garcia-Pardo,
Angeles; Orend, Gertrud (1)
CS (1) Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse
66, 4058, Basel: goren@fmi.ch Switzerland
SO Cancer Research. (December 1, 2001) Vol. 61, No. 23, pp. 8586-8594.
http://cancerres.aacrjournals.org/. print.
ISSN: 0008-5472.

DT Article
LA English

ANSWER 10 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
L5 2001:512824 BIOSIS
AN PREV200100512824
DN PR-39 coordinates changes in vascular smooth muscle cell adhesive strength
TI and locomotion by modulating cell surface heparan sulfate-matrix
interactions.
AU Chon, John H.; Houston, Michelle M.; Xu, Chengpei; Chaikof, Elliot L. (1)
CS (1) Emory University, 1639 Pierce Drive, Room 5105, Atlanta, GA, 30322:
echaikof@emory.edu USA
SO Journal of Cellular Physiology. (November, 2001) Vol. 189, No. 2, pp.
133-143. print.
ISSN: 0021-9541.
DT Article

LA English
SL English

L5 ANSWER 11 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:218581 BIOSIS
DN PREVIEW99900218581

TI Syndecan-4 signals cooperatively with Integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.

AU Saoncelia, Stefania; Echtermeyer, Frank; Denhez, Fabienne; Nowlen, Julie K.; Mosher, Deane F.; Robinson, Stephen D.; Hynes, Richard O.; Goetinck, Paul F. (1)

CS (1) Cutaneous Biology Research Center, 13th Street, MGH-East, Building 149, Charlestown, MA, 02129 USA
SO Proceedings of the National Academy of Sciences of the United States of America, (March 16, 1999) Vol. 96, No. 6, pp. 2805-2810.
ISSN: 0027-8424.

DT Article
LA English
SL English

L5 ANSWER 12 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001431465 EMBASE
TI Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.

AU Huang W.; Chiquet-Ehrismann R.; Moyano J.V.; Garcia-Pardo A.; Orend G. G.; Orend, F.; Miescher Inst. For Biomed. Res., Maulbeeralstrasse 66, 4058 Basel, Switzerland. goren@iml.ch
SO Cancer Research, (1 Dec 2001) 61/23 (8586-8594).
Refs: 56
ISSN: 0008-5472 CODEN: CUREA8

CY United States
DT Journal: Article
FS 016 Cancer
LA English
SL English

L5 ANSWER 13 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001356736 EMBASE
TI PR-39 coordinates changes in vascular smooth muscle cell adhesive strength and locomotion by modulating cell surface heparan sulfate-matrix interactions.

AU Chon J.H.; Houston M.M.; Xu C.; Chaikof E.L.
CS E.L. Chaikof, Emory University, 1639 Pierce Drive, Atlanta, GA 30322, United States. echaikof@emory.edu (2001) 189/2 (133-143).
Refs: 49
ISSN: 0021-9541 CODEN: JCLLAX

CY United States
DT Journal: Article
FS 002 Physiology
LA English
SL English

L5 ANSWER 14 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1999114471 EMBASE
TI Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.

AU Saoncelia S.; Echtermeyer F.; Denhez F.; Nowlen J.K.; Mosher D.F.; Robinson S.D.; Hynes R.O.; Goetinck P.F.
CS P.F. Goetinck, Cutaneous Biology Research Center, MGH-East, Building 149,

SO 13th Street, Charlestown, MA 02129, United States.
pgoetinck@crb.mgh.harvard.edu
Proceedings of the National Academy of Sciences of the United States of America, (1999) 96/6 (2805-2810).
Refs: 33
ISSN: 0027-8424 CODEN: PNASA6

CY United States
DT Journal: Conference Article
FS 029 Clinical Biochemistry
LA English
SL English

L5 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 2002:720593 CAPLUS
TI Syndecan-4 Modulates Focal Adhesion Kinase Phosphorylation

AU Wilcox-Adelman, Sarah A.; Denhez, Fabienne; Goetinck, Paul F.
CS Massachusetts General Hospital, Cutaneous Biology Research Center, Harvard Medical School, Charlestown, MA, 02129, USA
SO Journal of Biological Chemistry (2002), 277(36), 32970-32977
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L5 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 2002:575295 CAPLUS
DN 137118777

TI Marker proteins and genes for human colon cancer, methods and compositions for their diagnostic, prognostic, and therapeutic uses

IN Schlegel, Robert; Berger, Allison
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

DT Patent
LA English
SL English

PI PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2002059376 AI 20020801 WO 2002-US2188 20020123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-263209 P 20010123
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 2002:548089 CAPLUS
TI A recombinant NH2-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan

AU Ferrari do Outeiro-Bernstein, Mariana A.; Nunes, Sara Santana; Andrade, Ana Carolina Magalhães; Alves, Tercia Rodrigues; Legrand, Chantal; Morandi, Veronica
CS Instituto de Biologia Roberto Alcântara Gomes, Departamento de Biologia

PRAI US 1999-124396P P 19990315
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1999-795994 CAPLUS

TI Gene probes used for genetic profiling in healthcare screening and planning

PCT Int. Appl., 745 pp.

LA English

PATENT NO.

W: AE

23

53
54

GB 1998-13
GB 1998-13

GB 1998-14

GB 1998-15
GB 1998-16

GB 1998-16
GB 1998-17

GB 1998-17

| | |
|----|------------|
| AN | 1999:79599 |
| DN | 132:31743 |

IN Roberts, G

CODEN: PIX
Parent
MT

PATENT NO.

W: AE DE

PLA

TM, TR, TT, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RM: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|------------|----|----------|---------------|----------|
| GB 2339200 | A1 | 20000119 | GB 1999-12914 | 19990604 |
| GB 2339200 | B2 | 20010912 | | |

A: AL, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, UK, FI,
 IE, FI

GB 1998-16086 A 19980724

GB 1998-17097 A 19980807

GB 1998-17943 A 19980819

L5 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1998-1999 CAPLUS

11 Rho-dependent manner in the assembly of focal adhesions and actin stress
12 synaescan-1 signals cooperatively with integrins in a

K.; Mosher, Deane F.; Robinson, Stephen D.; Hynes, Richard O.; Goettinck, David E.

SO Proceedings of the National Academy of Sciences of the United States of General Hospital, Charlestown, MA, 02129, USA

PB National Academy of Sciences

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2002:221323 USPATFULL

Porter, Mark W., Germantown, MD, UNITED STATES
Johnson, Kory B, Bethesda, MD, UNITED STATES

PI US 2002119462 A1 20020829
ERASIMIL, MICHAEL A.; GELMANILOW, MD, UNITED STATES

| | |
|-----------------|---------------|
| US 2000-244880P | 20001102 (60) |
| US 2001-290039B | 20010511 (60) |

| | |
|-----------------|---------------|
| US 2001-292538P | 20010322 (80) |
| US 2001-295798P | 20010606 (60) |

US 2001-303459P 20010709 (60)

T086 INCI NET

INCL INCLM: 435/006.000
 INCLM: 702/020.000
 NCLM: 435/006.000
 NCLM: 702/020.000
 IC [7]
 ICM: C120001-68
 ICS: G06F019-00; G01N033-48; G01N033-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 35 USPATFULT
 AN 2002:206116 USPATFULT
 TI Toxicant-induced differential gene expression
 IN Rejzhaat-Olson, John F., Montclair, NJ, UNITED STATES
 PI US 2002110808 AI 20020815
 AI US 2000-489220 AI 20000121 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 5161
 INCL INCLM: 435/006.000
 INCLM: 435/091.200; 536/023.100
 NCLM: 435/006.000
 NCLM: 435/091.200; 536/023.100
 IC [7]
 ICM: C120001-68
 ICS: C07H021-02; C07H021-04; C12P019-34
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 35 USPATFULT
 AN 2002:92068 USPATFULT
 TI Methods of modulating wound healing and angiogenesis
 IN Goelink, Paul F., Boston, MA, UNITED STATES
 PI US 2002048585 AI 20020425
 AI US 2001-900288 AI 20010706 (9)
 PRAI US 2000-216247P 20000706 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1466
 INCL INCLM: 424/155.100
 INCLM: 514/012.000; 514/044.000
 NCLM: 424/155.100
 NCLM: 514/012.000; 514/044.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K039-395; A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 35 USPATFULT
 AN 2002:22107 USPATFULT
 TI POLYPEPTIDES WITH A4 INTEGRIN SUBUNIT RELATED ACTIVITY
 IN MCCARTHY, JAMES B., MINNEAPOLIS, MN, UNITED STATES
 FURCH, LEO T., MINNEAPOLIS, MN, UNITED STATES
 IIDA, JOEL, SHOREVIEW, MN, UNITED STATES
 PA Regents of the University of Minnesota, Minneapolis, MN (U.S. corporation)
 PI US 2002012842 AI 20020131
 AI US 1998-10714 AI 19980122 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 1102
 INCL INCLM: 435/007.100
 INCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
 427/002.100; 623/001.100
 NCLM: 435/007.100
 NCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;

IC [7]
 427/002.100; 623/001.100
 ICM: A61K038-00
 ICS: A61K038-04; C07K017-00; C07K016-00; C07K014-00; C07K005-00;
 C07K004-00; C07K002-00; C07K007-00; C12M001-00; G01N033-53; A61L002-00;
 A61F002-06; B05D003-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 35 USPATFULT
 AN 2002:16917 USPATFULT
 TI Growth stimulation of biological cells and tissue by electromagnetic
 IN fields and uses thereof
 WOLF, David A., Houston, TX, UNITED STATES
 PA Goodwin, Thomas J., Friendswood, TX, UNITED STATES
 PI US 2002009797 AI 20020124
 AI US 2001-798854 AI 20010228 (9)
 RLI Division of Ser. No. US 2000-587028, filed on 2 Jun 2000, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 1200
 INCL INCLM: 435/289.100
 INCLM: 435/298.200; 435/173.800
 NCLM: 435/289.100
 NCLM: 435/298.200; 435/173.800
 IC [7]
 ICM: C12M003-00
 ICS: C12N013-00

L5 ANSWER 31 OF 35 USPATFULT
 AN 2000:18280 USPATFULT
 TI Nucleic acid sequence of senescence associated gene
 IN Funk, Walter, Hayward, CA, United States
 PA Genon Corporation, Menlo Park, CA, United States (U.S. corporation)
 PI US 6025194 20000215
 AI US 1997-974180 19971119 (8)
 DT Utility
 FS Granted
 LN.CNT 4667
 INCL INCLM: 435/320.100
 INCLM: 536/023.100; 536/023.500; 536/024.100; 435/320.100; 435/325.000
 NCLM: 435/320.100
 NCLM: 435/325.000; 536/023.100; 536/023.500; 536/024.100
 IC [7]
 ICM: C07H021-04
 ICS: C12N015-63; C12N015-85; C12N015-11
 ICS: 536/23.5; 536/23.1; 536/24.1; 435/320.1; 435/325

EXF 536/23.5; 536/23.1; 536/24.1; 435/320.1; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 35 USPATFULT
 AN 1999:12906 USPATFULT
 TI Synuclein mediated modulation of tissue repair
 IN Gallo, Richard L., Natick, MA, United States
 Bernfield, Merton, Boston, MA, United States
 PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
 PI US 5863897 19990126
 AI US 1996-728333 19961010 (8)
 RLI Continuation of Ser. No. US 1994-310722, filed on 22 Sep 1994, now
 DT Utility patented, Pat. No. US 5654273
 FS Granted
 LN.CNT 666
 INCL INCLM: 514/012.000

INCL: 514/008.000
 NCL: 514/012.000
 NCLM: 514/008.000
 NCLS: 514/008.000
 IC [6]
 ICM: A61K038-00
 ICS: A61K038-02; C07K005-00; C07K007-00
 EXF 514/12; 514/8; 530/324
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 35 USPATFULT
 AN 1998:159925 USPATFULT
 TI Suppression of tumor cell growth by syndecan-1 ectodomain
 IN Jalkanen, Markku, Finland
 PA Maki, Marku, Sato, Finland
 PA Biotie Therapies Ltd., Turku, Finland (non-U.S. corporation)
 PI US 5651993 19981222
 AI US 1995-488199 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-258862, filed on 13 Jun 1994,
 now abandoned
 DT Utility
 FS Granted
 IN.CNT 1585
 INCL INCLM: 514/012.000
 INCLS: 514/008.000; 514/021.000; 530/395.000
 NCL NCLM: 514/012.000
 NCLS: 514/008.000; 514/021.000; 530/395.000
 IC [6]
 ICM: A61K038-17
 ICS: A61K038-16; C07K014-47; C07K014-705
 EXF 514/8; 514/12; 514/21; 436/64; 530/380; 530/395; 530/808; 530/827
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 35 USPATFULT
 AN 97:68443 USPATFULT
 TI Syndecin mediated modulation of tissue repair
 IN Gallo, Richard L., Natick, MA, United States
 PA Bernfield, Merton, Boston, MA, United States
 PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
 PI US 5654273 19970805
 AI US 1994-310722 19940922 (8)
 DT Utility
 FS Granted
 IN.CNT 748
 INCL INCLM: 514/012.000
 INCLS: 514/008.000; 530/324.000
 NCL NCLM: 514/012.000
 NCLS: 514/008.000; 530/324.000
 IC [6]
 ICM: A61K038-00
 ICS: C07K005-00; C07K007-00; C07K017-00
 EXF 514/12; 514/8; 530/324
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 35 USPATFULT
 AN 96:7785 USPATFULT
 TI Construction and use of synthetic constructs encoding syndecan
 IN Saunders, Scott, Boston, MA, United States
 PA Bernfield, Merton, Boston, MA, United States
 PA Kato, Masato, Boston, MA, United States
 PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
 PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)

PI US 5486599 19960123
 AI US 1993-78683 19930617 (8)
 RLI Continuation-in-part of Ser. No. US 1991-757654, filed on 6 Sep 1991,
 now abandoned And a continuation-in-part of Ser. No. US 1992-856869,
 filed on 24 Mar 1992, now abandoned which is a continuation-in-part of
 Ser. No. US 1991-746797, filed on 12 Aug 1991, now abandoned which is a
 continuation-in-part of Ser. No. US 1989-331585, filed on 29 Mar 1989,
 now abandoned
 DT Utility
 FS Granted
 IN.CNT 3939
 INCL INCLM: 530/395.000
 INCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
 NCL NCLM: 530/395.000
 NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
 IC [6]
 ICM: C07K014-435
 ICS: C07K019-00; C12N015-12; C12N015-62
 EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 11 and cancer?
 L7 37 L1 AND CANCER?
 => d 1-37
 L7 ANSWER 1 OF 37 MEDLINE
 AN 2001234892 Pubmed ID: 11251555
 DN 21143694
 TI Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers.
 AU Lundqvist K; Schmidtsen A
 CS Department of Dermatology, Biomedical Center, B14, Lund University, Torshagen S-221 85 Lund, Sweden.
 SO BRITISH JOURNAL OF DERMATOLOGY. (2001 Feb) 144 (2) 254-9.
 Journal code: 0004041. ISSN: 0007-0963.
 CY England; United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200105
 ED Entered STN: 20010517
 Last Updated on STN: 20010517
 Entered Medline: 20010503
 L7 ANSWER 2 OF 37 MEDLINE
 AN 2001139297 Pubmed ID: 11169953
 DN 21101228
 TI Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines.
 AU Zivbel I; Brill S; Halpern Z; Moskovitz S; Yaron A; Papa M
 CS Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.. isab@casim.health.gov.il
 SO INTERNATIONAL JOURNAL OF CANCER. (2001 Feb 1) 91 (3) 316-21.
 Journal code: 0042124. ISSN: 0020-7136.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200103
 ED Entered STN: 20010404
 Last Updated on STN: 20010404
 Entered Medline: 20010308
 L7 ANSWER 3 OF 37 CANCERLIT
 AN 2001101228
 DN 21101228 Pubmed ID: 11169953
 TI Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines.
 AU Zivbel I; Brill S; Halpern Z; Moskovitz S; Yaron A; Papa M
 CS Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.. isab@casim.health.gov.il
 SO INTERNATIONAL JOURNAL OF CANCER. (2001 Feb 1) 91 (3) 316-21.
 Journal code: 0042124. ISSN: 0020-7136.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Priority Journals
 OS MEDLINE 2001139297
 EM 200103
 ED Entered STN: 20010515
 Last Updated on STN: 20010515
 L7 ANSWER 4 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002:409836 BIOSIS
 DN PREV200200409836
 TI Gene expression profiles of organ-specific metastases in breast cancer.
 AU Lee, Hyerim (1); Smith, Jeffrey W. (1)
 CS (1) The Burnham Institute, La Jolla, CA USA
 SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2002) Vol. 43, pp. 905. print.
 Meeting, info.: 93rd Annual Meeting of the American Association for Cancer Research San Francisco, California, USA April 06-10, 2002
 ISSN: 0197-016X.
 DT Conference
 LA English
 L7 ANSWER 5 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002:260469 BIOSIS
 DN PREV200200260469
 TI Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements.
 AU Brockstedt, Ulrika; Dobra, Katalin; Nurminen, Mervi; Hjerppe, Anders (1)
 CS (1) Department of IMPI, Division of Pathology, Karolinska Institutet, Huddinge University Hospital, F46, S-14186, Huddinge:
 anders.hjerppe@pathlab.hs.sll.se Sweden
 SO Experimental Cell Research, (April 1, 2002) Vol. 274, No. 2, pp. 235-245.
 http://www.academypress.com/ectr. print.
 ISSN: 0014-4827.
 DT Article
 LA English
 L7 ANSWER 6 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002:111679 BIOSIS
 DN PREV200200111679
 TI Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas.
 AU Mundhenke, Christoph; Meyer, Kristy; Drew, Sally; Friedl, Andreas (1)
 CS (1) Department of Pathology and Laboratory Medicine, Clinical Sciences Center, 600 Highland Ave., R4-850, Madison, WI, 52792-8550:
 a.friedl@facstaff.wisc.edu USA
 SO American Journal of Pathology, (January, 2002) Vol. 160, No. 1, pp. 185-194. http://ajp.amjpathol.org/. print.
 ISSN: 0002-9440.
 DT Article
 LA English
 L7 ANSWER 7 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:152884 BIOSIS
 DN PREV200100152884
 TI Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers.
 AU Lundqvist, K.; Schmidtsen, A. (1)
 CS (1) Department of Dermatology and Department of Cell and Molecular Biology, Lund University, Torshagen, Biomedical Center, B14, S-221 85, Lund: artur.schmidtsen@derm.lu.se Sweden
 SO British Journal of Dermatology, (February, 2001) Vol. 144, No. 2, pp. 254-259. print.
 ISSN: 0007-0963.
 DT Article
 LA English
 SL English
 L7 ANSWER 8 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:81626 BIOSIS
 DN PREV20010081626
 TI Heparan sulfate proteoglycan expression in breast carcinomas and its impact on FGF-2 signaling.
 L7 ANSWER 9 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002:409836 BIOSIS

- AU Mundhenke, C. (1); Maass, N.; Meyer, K. (1); Drew, S. (1); Friedl, A. (1)
 CS (1) Dept. of Pathology, University of Wisconsin, Madison, WI USA
 SO Breast Cancer Research and Treatment, (November, 2000) Vol. 64, No. 1, pp.
 115. Print.
 Meeting Info.: 23rd Annual San Antonio Breast Cancer Symposium San
 Antonio, Texas, USA December 06-09, 2000
 ISSN: 0167-6606.
 DT Conference
 LA English
 SL English
- L7 ANSWER 9 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001.69174 BIOSIS
 DN PREV200100069174
 TI Soluble and matrix-associated heparan sulfate proteoglycans increase
 expression of erb-B2 and erb-B3 in colon cancer cell lines.
 AU Zivbel, Isabel (1); Brill, Shlomo; Halpern, Zamil; Moskovitz, Sharon;
 Yayon, Avner; Papa, Moshe
 CS (1) Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv
 Sourasky Medical Center, Weizmann 6, Tel Aviv; isab@tasmc.health.gov.il
 SO International Journal of Cancer, (1 February, 2001) Vol. 91, No. 3, pp.
 316-321. Print.
 ISSN: 0020-7136.
 DT Article
 LA English
 SL English
- L7 ANSWER 10 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2000.363289 BIOSIS
 DN PREV200000363289
 TI Altered patterns of heparan sulphate proteoglycan expression in human
 epithelial ovarian cancer.
 AU Davies, E. J. (1); McGown, A. (1); Shanks, J.; David, G.; Gallagher, J.
 T.; Jayson, G.
 CS (1) Department of Drug Development and Imaging, Paterson Institute for
 Cancer Research, Manchester UK
 SO British Journal of Cancer, (July, 2000) Vol. 83, No. Supplement 1, pp. 29.
 Print.
 Meeting Info.: Meeting of the British Cancer Research Brighton, UK July
 09-12, 2000
 ISSN: 0007-0920.
 DT Conference
 LA English
 SL English
- L7 ANSWER 11 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001431465 EMBASE
 TI Interference of tenascin-C with syndecan-4 binding to
 fibronectin blocks cell adhesion and stimulates tumor cell proliferation.
 AU Huang W.; Chiquet-Ehrismann R.; Moyano J.V.; Garcia-Parro A.; Orend G.
 G. Orend, F. Miescher Inst. for Biomed. Res., Maulbeerstrasse 66, 4058
 Basel, Switzerland. goren@fmi.ch
 SO Cancer Research, (1 Dec 2001) 61/23 (8586-8594).
 Refs: 56
 ISSN: 0008-5472 CODEN: CRRBAS
 DT United States
 LA English
 SL English
- L7 ANSWER 12 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001082395 EMBASE
- TI Immunohistochemical studies on proteoglycan expression in normal skin and
 chronic ulcers.
 AU Lundqvist K.; Schmidtchen A.
 CS A. Schmidtchen, Department of Dermatology, Biomedical Center, Lund
 University, Tomteavägen, S-221 85 Lund, Sweden.
 arthur.schmidtchen@derm.lu.se
 SO British Journal of Dermatology, (2001) 144/2 (254-259).
 Refs: 23
 ISSN: 0007-0963 CODEN: BJDEAZ
 CY United Kingdom
 DT Journal: Article
 FS 005 General Pathology and Pathological Anatomy
 LA 013 Dermatology and Venereology
 SL English
- L7 ANSWER 13 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001021696 EMBASE
 TI Soluble and matrix-associated heparan sulfate proteoglycans increase
 expression of erb-b2 and erb-b3 in colon cancer cell lines.
 AU Zivbel I.; Brill S.; Halpern Z.; Moskovitz S.; Yayon A.; Papa M.
 I. Zivbel, Liver Metastasis Research Group, Gastroenterology Institute,
 Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
 isab@tasmc.health.gov.il
 SO International Journal of Cancer, (1 Feb 2001) 91/3 (316-321).
 Refs: 25
 ISSN: 0020-7136 CODEN: IJCNAM
 CY United States
 DT Journal: Article
 FS 016 Cancer
 LA 048 Gastroenterology
 SL English
- L7 ANSWER 14 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2000253987 EMBASE
 TI Differentiation of mesothelioma cells is influenced by the expression of
 proteoglycans.
 AU Dobra K.; Andang M.; Syrokov A.; Karamanos N.K.; Hjerpe A.
 A. Hjerpe, Department of IMPI, Division of Pathology, Karolinska
 Institutet, S-14186 Stockholm, Sweden. anders.hjerpe@pathlab.hi.se
 SO Experimental Cell Research, (10 Jul 2000) 258/1 (12-22).
 Refs: 44
 ISSN: 0014-4827 CODEN: ECREAL
 CY United States
 DT Journal: Article
 FS 016 Cancer
 LA 029 Clinical Biochemistry
 SL English
- L7 ANSWER 15 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998365945 EMBASE
 TI Syndecan-1 expression in malignant mesothelioma: Correlation with cell
 differentiation, Wt1 expression, and clinical outcome.
 AU Kumar-Singh S.; Jacobs W.; Dhane K.; Weyn B.; Bogers J.; Weyler J.; Van
 Marck E.
 CS Prof. E. Van Marck, Laboratory of Pathology, University of Antwerp,
 Universiteitsplein 1, B-2610 Antwerp, Belgium.
 eric.van.marck@uia.ac.be
 SO Journal of Pathology, (1998) 186/3 (300-305).
 Refs: 30
 ISSN: 0022-3417 CODEN: JPTLAS
 CY United Kingdom

DT Journal: Article
FS 005 General Pathology and Pathological Anatomy
015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
LA English
SL English
L7 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2002 ACS
AN 2002:575295 CAPLUS
DN 137:138777
TI Marker proteins and genes for human colon cancer, methods and compositions for their diagnostic, prognostic, and therapeutic uses
IN Schlegel, Robert; Berger, Allison
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 112 pp.
RE.CNT 6
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 200205376 A1 20020801 WO 2002-US2188 20020123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NI, NO, NU, OI, PA, PE, PG, PH, PI, PL, PT, PU, PZ, RE, RU, RW, SA, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, BR, BU, BU, RU, TJ, TM
RW: GH, GM, KE, LS, LM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2001-263620P P 20010123
THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
L7 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2002 ACS
AN 2002:52471 CAPLUS
DN 136:350221
TI Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent
AU Chang, Bey-Dih; Swift, Mari E.; Shen, Mei; Fang, Jing; Brodeur, Eugenia V.; Roninson, Igor B.
CS Department of Molecular Genetics, University of Illinois, Chicago, IL, 60607-7170, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2002), 99(1), 389-394
CODEN: PNASAB; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
RE.CNT 38
THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
L7 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2002 ACS
AN 2001:828415 CAPLUS
DN 137:89412
TI Detection of variations in the DNA methylation profile of genes in the Berlin, Kurt; Piepenbrock, Christian; Olek, Alexander
IN Epigenomics A.-G., Germany
PA PCT Int. Appl., 636 pp.
SO CODEN: PIXXD2
DT Patent

LA German
FAN.CNT 68
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2001077373 A2 20011018 WO 2001-XA1486 20010406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NI, NO, NU, OI, PA, PE, PG, PH, PI, PL, PT, PU, PZ, RE, RU, RW, SA, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, BR, BU, BU, RU, TJ, TM
RW: GH, GM, KE, LS, LM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG
DE 10019058 A1 20011220 DE 2000-10019058 20000406
WO 2001077373 A2 20011018 WO 2001-DE1486 20010406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NI, NO, NU, OI, PA, PE, PG, PH, PI, PL, PT, PU, PZ, RE, RU, RW, SA, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, BR, BU, BU, RU, TJ, TM
RW: GH, GM, KE, LS, LM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BU, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG
PRAI DE 2000-10019058 A 20000406
WO 2001-DE1486 W 20010406
L7 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2002 ACS
AN 2001:219091 CAPLUS
DN 135:178930
TI Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers
AU Lundqvist, K.; Schmaltden, A.
CS Department of Dermatology and Department of Cell and Molecular Biology, Lund University, Lund, S-221 85, Sweden.
SO British Journal of Dermatology (2001), 144(2), 254-259
CODEN: BJDEAZ; ISSN: 0007-0963
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 23
THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
L7 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2002 ACS
AN 2001:55782 CAPLUS
DN 135:32009
TI Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines
AU Zivbel, Isabel; Brill, Shlomo; Halpern, Zamir; Moskovitz, Sharon; Yayon, Avner; Papa, Moshe
CS Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv-Jaffa, Israel, 61000, 316-321
SO International Journal of Cancer (2001), 91(3), 316-321
CODEN: IJCANM; ISSN: 0020-7136
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 25
THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
L7 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2002 ACS
AN 2000:893681 CAPLUS
DN 134:220676

71 Transcription analysis of fibroblast cells immediate-early after human
 cytomegalovirus infection
 AU Kenzelmann, Marc; Muhlemann, Kathrin
 CS Institute of Medical Microbiology, University of Bern, Bern, 3010, Switz.
 SO Journal of Molecular Biology (2000), 304(5), 741-751
 PB CODEN: JMOBKA; ISSN: 0022-2836
 DT Academic Press
 LA English
 RE CNT 51
 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:666752 CAPLUS
 DN 133:232876
 TI Methods of modulating cell attachment and migration using a modulator of
 syndecan-4 ectodomain binding with a counterligand
 IN Goetinck, Paul
 PA The General Hospital Corporation, USA
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 P1 WO 2000055181 A1 20000921 WO 2000-US6740 20000315
 W: CA, JP
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 PRAI US 1999-124396P 19990315
 RE CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:324878 CAPLUS
 DN 128:318018
 TI Construction of transgenic mice expressing a syndecan 1 gene in regions of
 hypothalamus for wt. regulation and therapy
 IN Bernfield, Merton; Reizes, Ofer
 PA Children's Medical Center Corp., USA
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 P1 WO 9820121 A1 19980514 WO 1997-US20003 19971106
 W: AL, AU, BA, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP,
 KR, KR, LC, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,
 SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GR, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CN, GA,
 CN, ML, MR, NE, SN, TD, TG
 AU 9852437 A1 19980529 AU 1998-52437 19971106
 EP 942567 A1 19990922 EP 1997-947327 19971106
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 US 6284729 B1 20010904 US 1998-73623 19980506
 PRAI US 1996-30758P P 19961106
 US 1997-965356 A1 19971106
 WO 1997-US20003 W 19971106

L7 ANSWER 24 OF 37 USPATFULL
 AN 2002:238813 USPATFULL
 TI Identification of disease predictive nucleic acids
 IN Becker, David J., Encinitas, CA, United States
 PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S.
 corporation)
 PI US 6451524 B1 20020917
 AI US 1998-200355 19981125 (9)
 DT Utility
 FS GRANTED
 LN CNT 1214
 INCL INCLM: 435/006.000
 INCLS: 536/023.100; 536/024.310
 NCLM: 435/006.000
 NCLS: 536/023.100; 536/024.310
 IC (7)
 ICM: C120001-68
 ICS: C07H021-04
 EXF 435/6; 435/375; 536/23.1; 536/24.31
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 37 USPATFULL
 AN 2002:221323 USPATFULL
 TI Molecular toxicology modeling
 IN Mendrick, Donna L., Mount Airy, MD, UNITED STATES
 Porter, Mark W., Germantown, MD, UNITED STATES
 Johnson, Kory R., Bethesda, MD, UNITED STATES
 Castle, Arthur L., Washington, DC, UNITED STATES
 Elashoff, Michael R., Germantown, MD, UNITED STATES
 PI US 2002119462 A1 20020829
 PRAI US 2001-917800 A1 20010731 (9)
 US 2000-222040P 20000731 (60)
 US 2000-244880P 20001102 (60)
 US 2001-290029P 20010511 (60)
 US 2001-290645P 20010515 (60)
 US 2001-292336P 20010522 (60)
 US 2001-295798P 20010606 (60)
 US 2001-297457P 20010613 (60)
 US 2001-298884P 20010619 (60)
 US 2001-303459P 20010709 (60)
 DT Utility
 FS APPLICATION
 INCL INCLM: 435/006.000
 INCLS: 702/020.000
 NCLM: 435/006.000
 NCLS: 702/020.000
 IC (7)
 ICM: C120001-68
 ICS: G06F019-00; G01N033-48; G01N033-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 26 OF 37 USPATFULL
 AN 2002:164420 USPATFULL
 TI Compositions and methods for treating viral infections
 IN Gelsinger, Frank B., Shreveport, LA, UNITED STATES
 Probe International Inc., Shreveport, LA, UNITED STATES (U.S.
 corporation)
 PI US 2002086034 A1 20020704
 AI US 2001-985581 A1 20011105 (9)
 RLI Division of Ser. No. US 2000-677554, filed on 2 Oct 2000, PATENTED
 Division of Ser. No. US 2000-482612, filed on 14 Jan 2000, PATENTED
 Division of Ser. No. US 1997-948782, filed on 10 Oct 1997, PATENTED

PRAI US 1996-28194P 19961010 (60)
 DT Utility
 FS APPLICATION
 LN CNT 3907
 INCL INCLM: 424/208.100 530/300.000; 435/005.000; 435/006.000; 435/007.100;
 INCLM: 424/188.100; 530/388.350; 530/324.000; 530/325.000; 530/326.000;
 435/339.100; 530/389.400
 NCLM: 424/208.100
 NCLM: 424/188.100; 530/300.000; 435/005.000; 435/006.000; 435/007.100;
 435/339.100; 530/388.350; 530/324.000; 530/325.000; 530/326.000;
 530/389.400
 IC [7]
 ICM: C120001-70
 ICS: G01N003-53; C07K002-00; C07K004-00; C120001-68; A61K039-21;
 C12N005-16; C12P021-08; C12N005-06; C07K014-00; C07K016-00; A61K038-04;
 A61K038-00; C07K005-00; C07K007-00; C07K017-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 27 OF 37 USPATFULT
 TI Methods of use of fibroblast growth factor, vascular endothelial growth
 factor and related proteins in the treatment of acute and chronic heart
 disease
 IN Franco, Wayne P., Rocky Hill, CT, UNITED STATES
 PI US 2002058612 A1 20020516
 AI US 2001-828330 A1 20010406 (9)
 PRAI US 2000-195624P 20000406 (60)
 DT Utility
 FS APPLICATION
 LN CNT 2636
 INCL INCLM: 514/002.000
 INCLM: 424/043.000
 NCLM: 514/002.000
 NCLM: 424/043.000
 IC [7]
 ICM: A61L009-04
 ICS: A61K038-18
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 28 OF 37 USPATFULT
 TI Methods of modulating wound healing and angiogenesis
 IN Goetnick, Paul F., Boston, MA, UNITED STATES
 PI US 2002046585 A1 20020425
 AI US 2001-900288 A1 20010706 (9)
 PRAI US 2000-216247P 20000706 (60)
 DT Utility
 FS APPLICATION
 LN CNT 1486
 INCL INCLM: 424/155.100
 INCLM: 514/012.000; 514/044.000
 NCLM: 424/155.100
 NCLM: 514/012.000; 514/044.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K039-395; A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 29 OF 37 USPATFULT
 TI Necglycan anticancer agents and uses thereof
 IN Sanderson, Ralph D., Maumelle, AR, UNITED STATES
 Pumphrey, Carla Y., Conway, AR, UNITED STATES

PI US 2002013264 A1 20020131
 AI US 2001-921032 A1 20010802 (9)
 RLI Continuation-in-part of Ser. No. US 2000-479139, filed on 7 Jan 2000.
 PENDING
 PRAI US 1999-115053P 19990108 (60)
 DT Utility
 FS APPLICATION
 LN CNT 1334
 INCL INCLM: 514/002.000
 INCLM: 514/054.000; 514/056.000; 514/059.000
 NCLM: 514/002.000
 NCLM: 514/054.000; 514/056.000; 514/059.000
 IC [7]
 ICM: A61K038-00
 ICS: A61K031-728; A61K031-727; A61K031-726; A61K031-721; A61K031-737
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 37 USPATFULT
 TI POLYPEPTIDES WITH A4 INTEGRIN SUBUNIT RELATED ACTIVITY
 IN MCCARTHY, JAMES B., MINNEAPOLIS, MN, UNITED STATES
 FURCHT, LEO T., MINNEAPOLIS, MN, UNITED STATES
 ILDA, JOYI, SHOREVIEW, MN, UNITED STATES
 PA Regents of the University of Minnesota, Minneapolis, MN (U.S.
 corporation)
 PI US 2002012942 A1 20020131
 AI US 1998-10714 A1 19980122 (9)
 DT Utility
 FS APPLICATION
 LN CNT 1102
 INCL INCLM: 435/007.100
 INCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
 427/002.100; 623/001.100
 NCLM: 435/007.100
 NCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
 427/002.100; 623/001.100
 IC [7]
 ICM: A61K038-00
 ICS: A61K038-04; C07K017-00; C07K016-00; C07K014-00; C07K005-00;
 C07K004-00; C07K002-00; C07K007-00; C12M001-00; G01N033-53; A61L002-00;
 A61P002-06; B05D003-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 31 OF 37 USPATFULT
 TI Growth stimulation of biological cells and tissue by electromagnetic
 fields and uses thereof
 IN Wolf, David A., Houston, TX, UNITED STATES
 Goodwin, Thomas J., Friendswood, TX, UNITED STATES
 PA National Aeronautics & Space Administration (U.S. corporation)
 PI US 2002009797 A1 20020124
 AI US 2001-798854 A1 20010228 (9)
 RLI Division of Ser. No. US 2000-587028, filed on 2 Jun 2000, ABANDONED
 DT Utility
 FS APPLICATION
 LN CNT 1200
 INCL INCLM: 435/289.100
 INCLM: 435/298.200; 435/173.800
 NCLM: 435/289.100
 NCLM: 435/298.200; 435/173.800
 IC [7]
 ICM: C12M003-00
 ICS: C12N013-00

L7 ANSWER 32 OF 37 USPATFILL
 AN 2002:930 USPATFILL
 TI Compositions and methods for treating viral infections
 IN Gelder, Frank B., Shreveport, LA, United States
 PA Probe International Inc., Shreveport, LA, United States (U.S. corporation)
 PI US 6335017 B1 20020101
 AI US 2000-677554 20001002 (9)
 RLT Division of Ser. No. US 2000-482612, filed on 14 Jan 2000, now patented, Pat. No. US 6258599 Division of Ser. No. US 1997-948782, filed on 10 Oct 1997, now patented, Pat. No. US 6043347
 PRAI US 1996-28194P 19961010 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3075
 INCL INCLM: 424/208.100
 INCL INCLM: 424/188.100; 530/300.000
 NCL NCLM: 424/208.100
 NCLM: 424/188.100; 530/300.000
 IC [7]
 ICM: A61K039-21
 ICS: A61K038-00
 EXF 424/188.1; 424/208.1; 530/300
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 37 USPATFILL
 AN 2001:107684 USPATFILL
 TI Compositions and methods for treating viral infections
 IN Gelder, Frank B., Shreveport, LA, United States
 PA Probe International Inc., Shreveport, LA, United States (U.S. corporation)
 PI US 6258599 B1 20010710
 AI US 2000-482612 20000114 (9)
 RLT Division of Ser. No. US 1997-948782, filed on 10 Oct 1997
 PRAI US 1996-28194P 19961010 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3062
 INCL INCLM: 435/339.100
 INCL INCLM: 435/005.000; 435/006.000; 435/007.100; 530/388.350; 530/324.000; 530/325.000; 530/326.000; 530/389.400
 NCL NCLM: 435/339.100
 NCLM: 435/005.000; 435/006.000; 435/007.100; 530/324.000; 530/325.000; 530/326.000; 530/388.350; 530/389.400
 IC [7]
 ICM: C12N005-16
 ICS: C12N001-70; C07K016-00; A61K038-00
 EXF 435/5; 435/6; 435/7.1; 435/339.1; 530/388.35; 530/324; 530/325; 530/326; 530/389.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 34 OF 37 USPATFILL
 AN 2000:37903 USPATFILL
 TI Compositions and methods for treating viral infections
 IN Gelder, Frank B., Shreveport, LA, United States
 PA Probe International Inc., Shreveport LA, United States (U.S. corporation)
 PI US 6043347 20000328
 AI US 1997-946782 19971010 (8)
 PRAI US 1996-28194P 19961010 (60)
 DT Utility
 FS Granted
 LN.CNT 3192
 INCL INCLM: 530/388.350

NCL INCLM: 435/005.000; 530/324.000; 530/325.000; 530/326.000; 530/389.400
 NCLM: 530/388.350
 NCLM: 435/005.000; 530/324.000; 530/325.000; 530/326.000; 530/389.400
 IC [7]
 ICM: C07K016-00
 ICS: C12N001-70; A61K038-00
 EXF 530/388.35; 530/324; 530/325; 530/326; 530/389.4; 435/5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 37 USPATFILL
 AN 2000:18280 USPATFILL
 TI Nucleic acid sequence of senescence associated gene
 IN Funk, Walter, Hayward, CA, United States
 PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
 PI US 6025194 20000215
 AI US 1997-974180 19971119 (8)
 DT Utility
 FS Granted
 LN.CNT 4667
 INCL INCLM: 435/320.100
 INCL INCLM: 536/023.100; 536/023.500; 536/024.100; 435/320.100; 435/325.000
 NCL NCLM: 435/320.100
 NCLM: 435/325.000; 536/023.100; 536/023.500; 536/024.100
 IC [7]
 ICM: C07H021-04
 ICS: C12N015-63; C12N015-85; C12N015-11
 EXF 536/23.5; 536/23.1; 536/24.1; 435/320.1; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 37 USPATFILL
 AN 1998:159925 USPATFILL
 TI Suppression of tumor cell growth by syndecan-1 ectodomain
 IN Jalkanen, Markku, Pilsanpisti, Finland
 PA Waki, Marku Salo, Finland
 PI US 5851993 19981222
 AI US 1995-488199 19950607 (8)
 RLT Continuation-in-part of Ser. No. US 1994-258862, filed on 13 Jun 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1585
 INCL INCLM: 514/012.000
 INCL INCLM: 514/008.000; 514/021.000; 530/395.000
 NCL NCLM: 514/012.000
 NCLM: 514/008.000; 514/021.000; 530/395.000
 IC [6]
 ICM: A61K038-17
 ICS: A61K038-16; C07K014-47; C07K014-705
 EXF 514/8; 514/12; 514/21; 436/64; 530/380; 530/395; 530/808; 530/827
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 37 USPATFILL
 AN 96:7785 USPATFILL
 TI Construction and use of synthetic constructs encoding syndecan
 IN Saunders, Scott, Boston, MA, United States
 TI Saunders, Scott, Boston, MA, United States
 PA Bernfield, Merton, Boston, MA, United States
 PA Kato, Masato, Boston, MA, United States
 PA The Board of Trustees of the Ireland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
 PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
 PI US 5486599 19960123
 AI US 1993-78683 19930617 (8)

R1 Continuation-in-part of Ser. No. US 1991-757654, filed on 6 Sep 1991,
now abandoned And a continuation-in-part of Ser. No. US 1992-856869,
filed on 24 Mar 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1991-746797, filed on 12 Aug 1991, now abandoned which is a
continuation-in-part of Ser. No. US 1989-31585, filed on 29 Mar 1989,
now abandoned

DT Utility
PS Granted
LN.CNT 3919
INCL INCLM: 530/395.000
INCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
536/023.500; 935/010.000; 935/047.000; 935/050.000; 935/070.000
NCLM: 530/395.000
NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
536/023.500

IC [6]
ICM: C07K014-435
ICG: C07K019-00; C12N015-12; C12N015-62
EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.